Pfizer (PFE), in slides discussing the Metsera (MTSR) deal, says it will provide any updates to its financial outlook in conjunction with the upcoming quarterly earnings.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Morning Movers: Metsera surges, Pfizer gains after acquisition pact
- Video: Metsera jumps after Pfizer strikes deal for obesity drugmaker
- Pfizer to acquire Metsera for $47.50 per share in cash upon closing
- Pfizer close to finalizing a $7.3B takeover of Metsera, FT reports
- M&A News: Metsera Stock (MTSR) Rallies over 60% on $7.3B Takeover by Pfizer